Abstract:Objective Hepatocellular carcinoma, characterized by high mortality rates, often exhibits limited responsiveness to conventional treatments such as surgery, radiotherapy, and chemotherapy. Therefore, identifying a sensitizer for cisplatin has become crucial. Dihydroartemisinin, known for its potent role of tumor treatment, arises as a prospective candidate for cisplatin sensitization in clinical settings. Methods A mouse model of liver tumor was established through chemical induction of DEN/TCPOBOP. Upon successful model establishment, ultrasound was employed to detect tumors, Hematoxylin and eosin staining was conducted for observation of liver tissue pathology, and ELISA was utilized to assess cytokine changes (IFN-γ, IL-2, IL-4, IL-10, TGF-β, IL-1β, CCL2, and CCL21) in peripheral blood, para-tumor tissues, and tumor tissues. The infiltration of CD8 + T cells and macrophages in tumor tissue sections was detected by immunofluorescence. Results Dihydroartemisinin combined with cisplatin obviously restrained the growth of liver tumors in mice and improved the weight and spleen loss caused by cisplatin. Cisplatin treatment of liver tumor mice increased the content of CCL2 and the number of macrophages in tumor tissues and promoted the formation of an immunosuppressive microenvironment. The combination therapy decreased the content of TGF-β in tumor tissues while increasing CCL2 levels in para-tumor tissues. Both combination therapy and cisplatin alone increased the number of CD8 + T cells in tumor tissue, but there was no difference between them. Conclusion Dihydroartemisinin combined with cisplatin obviously prevented the deterioration of liver tumor in hepatocellular carcinoma mice and improve the therapeutic effect of cisplatin by improving the immunosuppressive microenvironment induced by cisplatin. Our findings provide a theoretical basis for considering dihydroartemisinin as an adjuvant drug for cisplatin in the treatment of hepatocellular carcinoma in the future.

Artesunate Exhibits Synergistic Anti-Cancer Effects with Cisplatin on Lung Cancer A549 Cells by Inhibiting MAPK Pathway.

The Effects Of Artesunate On The Expression Of Egfr And Abcg2 In A549 Human Lung Cancer Cells And A Xenograft Model

Artesunate Impairs Growth in Cisplatin-Resistant Bladder Cancer Cells by Cell Cycle Arrest, Apoptosis and Autophagy Induction

Dihydroartemisinin sensitizes Lewis lung carcinoma cells to carboplatin therapy via p38 mitogen-activated protein kinase activation.

Artesunate and Sorafenib: Combinatorial Inhibition of Liver Cancer Cell Growth.

Artesunate inhibits lung cancer cells via regulation of mitochondrial membrane potential and induction of apoptosis

Dihydroartemisinin breaks the immunosuppressive tumor niche during cisplatin treatment in Hepatocellular carcinoma

Artesunate possesses anti-leukemia properties that can be enhanced by arsenic trioxide.

Arsenic Trioxide and Artemisinin Act Synergistically to Kill Tumor Cells in Vitro

Synergistic Effects of Taurine and Cisplatin on Lung Cancer Cells (A549)

The synergistic effect of resveratrol in combination with cisplatin on apoptosis via modulating autophagy in A549 cells.

Artemisinin Derivative Artesunate Induces Radiosensitivity in Cervical Cancer Cells in Vitro and in Vivo

Artesunate Exerts an Anti-Immunosuppressive Effect on Cervical Cancer by Inhibiting PGE2 Production and Foxp3 Expression.

Artesunate promoted anti-tumor immunity and overcame EGFR-TKI resistance in non-small-cell lung cancer by enhancing oncogenic TAZ degradation

Antitumour effects of artesunate via cell cycle checkpoint controls in human oesophageal squamous carcinoma cells

Artesunate Sensitizes Ovarian Cancer Cells To Cisplatin By Downregulating Rad51

Arteannuin B Enhances the Effectiveness of Cisplatin in Non-Small Cell Lung Cancer by Regulating Connexin 43 and MAPK Pathway

Synergistic Effect of Eicosapentaenoic Acid and Cisplatin on A-549 Human Lung Cancer Cell Line

Artesunate pErk up HepG2 cells to die through apoptosis in vitro

Artesunate Enhances Radiosensitivity of Human Non-Small Cell Lung Cancer A549 Cells Via Increasing NO Production to Induce Cell Cycle Arrest at G2/M Phase.

Artemisinin and Its Derivatives Can Significantly Inhibit Lung Tumorigenesis and Tumor Metastasis Through Wnt/β-catenin Signaling